Lee H. Kalowski
CFO & PresidentMr. Lee H. Kalowski, MBA, is the President and Chief Financial Officer at Q32 Bio Inc. since 2024 and was its Treasurer. Mr. Kalowski previously served as Legacy Q32’s Interim Chief Financial Officer since October 2023 and has also served as a consultant to the life sciences industry since October 2023. He serves as Independent Director at Aro Biotherapeutics Company. He had been the Chief Financial Officer of Bicycle Therapeutics plc since August 1, 2017 until June 22, 2023 and served as its President since January 2019 until June 22, 2023. Prior to joining Bicycle, Mr. Kalowski served as the Chief Financial Officer of Tokai Pharmaceuticals, Inc. from September 2014 to August 31, 2016. Mr. Kalowski served as a Vice President of Crédit Suisse AG, Research Division. He was a part of the global biotechnology equity research team. Prior to joining Tokai, He served as vice president, global biotechnology equity research at Credit Suisse. In this role, He served as a senior research analyst covering the biotechnology industry, including companies in the prostate cancer therapeutic area. He worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Mr. Kalowski spent three years in equity research, serving as a senior associate on Sanford C. Bernstein’s Institutional Investor-ranked global pharmaceutical team. He has also worked in mergers and acquisitions with Johnson & Johnson’s pharmaceutical group, where He was involved in the analysis and execution of several successfully completed biotech acquisitions and in the analysis of various expansion plans. His experience also includes medical device and biopharma private equity investing with Frazier Health Ventures and has edited for “The Pink Sheet”. Mr. Kalowski holds an M.B.A. in Finance and Health Care Management from the Wharton School of the University of Pennsylvania and a B.A. Phi Beta Kappa, from Union College, where he studied biology and economics.
Positions
- Company NameQ32 Bio Inc.Stock CodeQTTBPositionCFO & PresidentColleagues
- JPJodie Pope MorrisonCEO & Director
- MTMark T. IwickiIndependent Chairman of the Board
- SMShelia M. VioletteCo-founder, Chief Scientific Officer & President of Research
- DADavid AppuglieseSenior VP & Head of People
- MMMaria MarzilliChief Business Officer
- KDKathleen D. LaPorteIndependent Director
- MTMary T. ThistleIndependent Director
- DSDavid S. GrayzelIndependent Director
